EUVIMEDEUVIMED entdecken
Crossref

Navigating Lymphedema: The Impact of Indocyanine Green Lymphography on Personalized Therapy Outcomes in Breast Cancer Patients

Atilla Soran, Kazim Senol, Kristin Lupinacci

Clinical Breast Cancer · 2025

DOI: 10.1016/j.clbc.2024.10.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2025. Verfasst von Atilla Soran und 2 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Department of Surgery, Magee-Womens Hospital Breast Cancer Clinic, Lymphedema Program, Pittsburgh, PA. Hauptthemen laut MEDLINE: Indocyanine Green, Lymphography, Breast Cancer Lymphedema, Breast Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Medical Center, University of Pittsburgh.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: To evaluate the role of Indocyanine Green Lymphography (ICG_L) in the early diagnosis and personalized management of breast cancer-related lymphedema (BCRL) among high-risk breast cancer (BC) survivors. METHODS: Patients who admitted to the UPMC Magee-Womens Hospital Lymphedema Program between October 2018 and December 2021 with episodic symptoms were enrolled into the study. Patient demographics, clinical characteristics, and outcomes were prospectively collected and retrospectively analysed. Lymphatic flow disruptions were identified and guided personalized therapeutic interventions were guided by ICG_L. RESULTS: Among 154 BC survivors, 184 arms were evaluated. Initial ICG_L showed 57.1% had no lymphedema, while 42.9% were classified as stage 1 to 3 lymphedema. Early diagnosis and personalized interventions provided improved outcomes, with only 4.3% developing clinical lymphedema after a median follow-up of 27 months. Patients exhibited stable or improved symptoms with individualized treatments such as manual lymphatic drainage, compression therapies, and physiotherapy. CONCLUSION: ICG_L evaluation is essential for patients at high-risk of developing BCRL. Early diagnosis before clinical onset of lymphedema, and ICG_L guided therapy significantly enhances the clinical outcomes and improves lymphedema management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Indocyanine GreenLymphographyBreast Cancer LymphedemaBreast NeoplasmsHumansFemaleMiddle AgedRetrospective StudiesAgedAdultPrecision MedicineLymphedemaManual Lymphatic Drainage

Stichwörter der Autor:innen

breast cancer related lymphedemaearly diagnosisindocyanine green lymphographylymphatic mappingpatient outcomes

Substanzen

Indocyanine Green

Autor:innen und Institutionen

  • UPMC Department of Surgery, Magee-Womens Hospital Breast Cancer Clinic, Lymphedema Program, Pittsburgh, PA.
  • UPMC Department of Surgery, Magee-Womens Hospital Breast Cancer Clinic, Lymphedema Program, Pittsburgh, PA. Electronic address: kazimsenol@gmail.com.

Förderung

  • Medical Center, University of Pittsburgh

Zitieren

APA

Soran, A., Senol, K., & Lupinacci, K. (2025). Navigating Lymphedema: The Impact of Indocyanine Green Lymphography on Personalized Therapy Outcomes in Breast Cancer Patients. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.10.010

Vancouver

Soran A, Senol K, Lupinacci K. Navigating Lymphedema: The Impact of Indocyanine Green Lymphography on Personalized Therapy Outcomes in Breast Cancer Patients. Clinical Breast Cancer. 2025. doi:10.1016/j.clbc.2024.10.010

BibTeX
@article{Soran2025,
  author = {Soran, Atilla and Senol, Kazim and Lupinacci, Kristin},
  title = {Navigating Lymphedema: The Impact of Indocyanine Green Lymphography on Personalized Therapy Outcomes in Breast Cancer Patients},
  journal = {Clinical Breast Cancer},
  year = {2025},
  doi = {10.1016/j.clbc.2024.10.010}
}
Kostenlos starten →